熱門資訊> 正文
Genentech多发性硬化症候选药物非奈替尼在后期试验中达到目标
2026-02-08 06:15
- Roche (RHHBY)-owned Genentech said that its multiple sclerosis asset fenebrutinib met its primary endpoint in a phase 3 trial.
- Fenebrutinib reduced the risk of disability progression by 12% compared to Ocrevus (ocrelizumab) as soon as 24 weeks in individuals with primary progressive multiple sclerosis.
- Genentech noted that clinical improvement was particularly notable in upper limb function.
- Fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, has a significant benefit over Ocrevus in that it is given as a pill.
- The candidate is also in two other phase 3 trials for relapsing multiple sclerosis.
More on Roche
- Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
- Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation
- Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
- ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
- Genentech in up to $1.7B RNAi licensing deal with SanegeneBio
推薦文章
美股機會日報 | 估值8500億美元！傳OpenAI最新融資規模將破千億美元；黃仁勛稱將發佈幾款世界前所未見的新芯片
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
